Lisata Therapeutics, Catalent announce global ADC licensing agreement

Lisata Therapeutics (LSTA) and Catalent announced a global product license agreement that allows Catalent to incorporate Lisata’s certepetide into antibody-drug conjugates, ADC, developed using Catalent’s SMARTag technology platform. Certepetide, a proprietary, internalizing RGD or “iRGD” cyclic peptide, is being tested by Lisata as a cancer therapeutic to be used in combination with other anti-cancer agents to enhance tumor targeting and penetration and improve treatment outcomes. Under the licensing agreement, Catalent gains worldwide, non-exclusive rights to develop and commercialize bioconjugate products containing certepetide and its analogs, including the ability to partner with third parties. As part of this collaboration, Catalent will have the right to evaluate certepetide and its analogs as SMARTag payloads in clinical studies across multiple ADCs targeting difficult-to-treat diseases, with the goal of creating a new class of targeted bioconjugate therapies.